[A25-92] Remdesivir (COVID-19, without supplemental oxygen, increased risk of progressing to severe COVID-19, ≥ 4 weeks, 3 to < 40 kg) - Benefit assessment according to §35a Social Code Book V
Last updated 15.10.2025
Project no.:
A25-92
Commission:
Commission awarded on 03.07.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Children and adolescents (at least 4 weeks of age and weighing 3 kg to < 40 kg) with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-92
| Project no. | Title | Status |
|---|---|---|
| A22-112 | Remdesivir (COVID-19, without supplemental oxygen, < 18 years of age) – Benefit assessment according to § 35a Social Code Book V | Commission completed |
| A21-38 | Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-04 | Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-113 | Remdesivir (COVID-19, requirement for additional oxygen supply, = 4 weeks - < 12 years of age) – Benefit assessment according to § 35a Social Code Book V | Commission completed |